Progress of Pharmaceutical Continuous Crystallization  

作　　者：Dejiang Zhang Shijie Xu Shichao Du Jingkang Wang Junbo Gong 

机构地区：[1]School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072. China [2]Collaborative Innovation Center of Chemical Science and Chemical Engineering, Tianjin University, Tianjin 300072, China

出　　处：《Engineering》2017年第3期354-364,共11页工程（英文）

基　　金：The authors are grateful to the financial support of the National Natural Science Foundation of China （81361140344, 21676179, and 21376164）, the ＂863＂ Program （2015AA021002）, the Major Project of Tianjin （15JCZDJC33200）, the National Major Scientific Instrument Development Project （21527812）, and the National Major Science and Technology Program for Water Pollution Control and Treatment （2015ZX07202-13）.

摘　　要：Crystallization is an important unit operation in the pharmaceutical industry. At present, most pharmaceutical crystallization processes are performed in batches. However, due to product variability from batch to batch and to the low productivity of batch crystallization, continuous crystallization is gaining increasing attention. In the past few years, progress has been made to allow the products of continuous crystallization to meet different requirements. This review summarizes the progress in pharmaceutical continuous crystallization from a product engineering perspective. The advantages and disadvantages of different types of continuous crystallization are compared, with the main difference between the two main types of crystallizers being their difference in residence time distribution. Approaches that use continuous crystallization to meet different quality requirements are summarized. Continuous crystallization has advantages in terms of size and morphology control. However, it also has the problem of a process yield that may be lower than that of a batch process, especially in the production of chirality crystals. Finally, different control strategies are compared.

关 键 词：Continuous crystallization PHARMACEUTICAL MSMPR Tubular crystallizer Control strategy 

分 类 号：N[自然科学总论]